Form 4: Lyra Therapeutics CEO Maria Palasis Granted Stock Options
SEC Form 4 Filing
Lyra Therapeutics' CEO, Maria Palasis, received stock options for 500,000 shares on March 18, 2024, vesting monthly over four years.
Summary
- Maria Palasis, the President and CEO of Lyra Therapeutics, was granted stock options for 500,000 shares of common stock on March 18, 2024.
- The exercise price of the options is $5.77 per share.
- The options vest in 48 equal monthly installments, starting after January 31, 2024, contingent upon continued service to Lyra Therapeutics.
- The expiration date for these options is March 17, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no immediate negative implications.
Positives
- The granting of stock options to the CEO aligns her interests with those of the shareholders, incentivizing her to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and vesting schedule of the grant are typical for a CEO of a company like Lyra Therapeutics.
Comparison to Industry Standards
- Stock option grants to CEOs in the biotech industry are common, with the size of the grant often tied to the company's market capitalization and the executive's role.
- Vesting schedules are typically structured to incentivize long-term performance, often over a period of 3-4 years, similar to the vesting schedule in this case.
- Comparable companies like Otonomy and Frequency Therapeutics also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase company value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| January 31, 2024 | Start date for the monthly vesting of the stock options. |
| March 18, 2024 | Date of the stock option grant. |
| March 20, 2024 | Date of the Form 4 filing. |
| March 17, 2034 | Expiration date of the stock options. |
Keywords
stock options, Lyra Therapeutics, Maria Palasis, CEO, equity, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.